6-Diazo-5-oxo-L-nor-Leucine (Standard)

6-Diazo-5-oxo-L-nor-Leucine (Standard) is the analytical standard of 6-Diazo-5-oxo-L-nor-Leucine. This product is intended for research and analytical applications. 6-Diazo-5-oxo-L-nor-Leucine (L-6-Diazo-5-oxonorleucine; DON) is a glutamine antagonist that irreversibly inhibits the catabolic effect of glutamine. 6-Diazo-5-oxo-L-nor-Leucine shows good anticancer activity (especially in pancreatic cancer) and reduces the self-renewal potential and metastatic capacity of tumour cells. 6-Diazo-5-oxo-L-nor-Leucine also possesses antibacterial and antiviral activity[1][2][3].

Product Specifications

CAS Number

[157-03-9]

Product Name Alternative

L-6-Diazo-5-oxonorleucine (Standard) ; DON (Standard)

UNSPSC

12352211

Hazard Statement

H301-H311-H331

Target

Antibiotic; Bacterial; Glutaminase; Influenza Virus; Reference Standards

Related Pathways

Anti-infection; Metabolic Enzyme/Protease; Others

Field of Research

Cancer; Infection

Smiles

N[C@@H](CCC(C=[N+]=[N-])=O)C(O)=O

Molecular Formula

C6H9N3O3

Molecular Weight

171.15

Precautions

P261-P264-P270-P271-P280-P302+P352-P304+P340-P330-P361+P364-P403+P233-P405-P501

References & Citations

[1]Willis RC, et al. The inhibition by 6-diazo-5-oxo-l-norleucine of glutamine catabolism of the cultured human lymphoblast. J Cell Physiol. 1977 Dec;93 (3) :375-82.|[2]Sharma NS, et al. Targeting tumor-intrinsic hexosamine biosynthesis sensitizes pancreatic cancer to anti-PD1 therapy. J Clin Invest. 2019 Oct 15.|[3]DeWald H A, et al. 6-diazo-5-oxo-l-norleucine, a new tumor-inhibitory substance. 1a preparation of l-, d-and dl-forms1b. Journal of the American Chemical Society, 1958, 80 (15) : 3941-3945.